Published in Cancer Res on July 15, 2003
Role of the TMPRSS2-ERG gene fusion in prostate cancer. Neoplasia (2008) 5.92
Antibody-based detection of ERG rearrangement-positive prostate cancer. Neoplasia (2010) 3.66
Mechanistic rationale for inhibition of poly(ADP-ribose) polymerase in ETS gene fusion-positive prostate cancer. Cancer Cell (2011) 3.53
An oncogene-tumor suppressor cascade drives metastatic prostate cancer by coordinately activating Ras and nuclear factor-kappaB. Nat Med (2010) 3.09
The role of SPINK1 in ETS rearrangement-negative prostate cancers. Cancer Cell (2008) 2.87
Consolidation of the cancer genome into domains of repressive chromatin by long-range epigenetic silencing (LRES) reduces transcriptional plasticity. Nat Cell Biol (2010) 2.38
Zbtb7a suppresses prostate cancer through repression of a Sox9-dependent pathway for cellular senescence bypass and tumor invasion. Nat Genet (2013) 2.11
KDM2A represses transcription of centromeric satellite repeats and maintains the heterochromatic state. Cell Cycle (2008) 1.90
Molecular alterations in primary prostate cancer after androgen ablation therapy. Clin Cancer Res (2005) 1.88
The oestrogen receptor alpha-regulated lncRNA NEAT1 is a critical modulator of prostate cancer. Nat Commun (2014) 1.84
Fine mapping and functional analysis of a common variant in MSMB on chromosome 10q11.2 associated with prostate cancer susceptibility. Proc Natl Acad Sci U S A (2009) 1.81
Telomerase reactivation following telomere dysfunction yields murine prostate tumors with bone metastases. Cell (2012) 1.75
Six1 expands the mouse mammary epithelial stem/progenitor cell pool and induces mammary tumors that undergo epithelial-mesenchymal transition. J Clin Invest (2009) 1.67
Hypermethylation of genes for diagnosis and risk stratification of prostate cancer. Cancer Invest (2009) 1.64
The TGF-β Signaling Regulator PMEPA1 Suppresses Prostate Cancer Metastases to Bone. Cancer Cell (2015) 1.55
Prognostic value and function of KLF4 in prostate cancer: RNAa and vector-mediated overexpression identify KLF4 as an inhibitor of tumor cell growth and migration. Cancer Res (2010) 1.54
MicroRNA let-7c suppresses androgen receptor expression and activity via regulation of Myc expression in prostate cancer cells. J Biol Chem (2011) 1.52
Genetic alteration and gene expression modulation during cancer progression. Mol Cancer (2004) 1.50
Immunosuppressive plasma cells impede T-cell-dependent immunogenic chemotherapy. Nature (2015) 1.42
GOLPH2 protein expression as a novel tissue biomarker for prostate cancer: implications for tissue-based diagnostics. Br J Cancer (2008) 1.41
Analysis of the 10q11 cancer risk locus implicates MSMB and NCOA4 in human prostate tumorigenesis. PLoS Genet (2010) 1.40
Clinical potential of the ERG oncoprotein in prostate cancer. Nat Rev Urol (2012) 1.17
Roles of neutrophil gelatinase-associated lipocalin (NGAL) in human cancer. Oncotarget (2014) 1.14
Modulated expression of WFDC1 during carcinogenesis and cellular senescence. Carcinogenesis (2008) 1.13
Epigenetic inactivation of the potential tumor suppressor gene FOXF1 in breast cancer. Cancer Res (2010) 1.13
Oncogenic activation of ERG: A predominant mechanism in prostate cancer. J Carcinog (2011) 1.13
Polymorphisms at the Microseminoprotein-beta locus associated with physiologic variation in beta-microseminoprotein and prostate-specific antigen levels. Cancer Epidemiol Biomarkers Prev (2010) 1.12
Impaired OXPHOS complex III in breast cancer. PLoS One (2011) 1.07
beta-Microseminoprotein binds CRISP-3 in human seminal plasma. Biochem Biophys Res Commun (2005) 1.07
Identification of ASF/SF2 as a critical, allele-specific effector of the cyclin D1b oncogene. Cancer Res (2010) 1.04
β4 Integrin signaling induces expansion of prostate tumor progenitors. J Clin Invest (2013) 1.03
EBP1, an ErbB3-binding protein, is decreased in prostate cancer and implicated in hormone resistance. Mol Cancer Ther (2008) 1.03
Oxidative stress and DNA methylation in prostate cancer. Obstet Gynecol Int (2010) 1.03
Prostate cancer predisposition loci and risk of metastatic disease and prostate cancer recurrence. Clin Cancer Res (2011) 1.01
The rs10993994 risk allele for prostate cancer results in clinically relevant changes in microseminoprotein-beta expression in tissue and urine. PLoS One (2010) 1.01
Genome-wide methylation analysis of prostate tissues reveals global methylation patterns of prostate cancer. Am J Pathol (2013) 1.00
Histone deacetylase inhibitors, valproic acid and trichostatin-A induce apoptosis and affect acetylation status of p53 in ERG-positive prostate cancer cells. Int J Oncol (2011) 1.00
A cell spot microarray method for production of high density siRNA transfection microarrays. BMC Genomics (2011) 0.98
Loss of cell-surface laminin anchoring promotes tumor growth and is associated with poor clinical outcomes. Cancer Res (2012) 0.98
The twist box domain is required for Twist1-induced prostate cancer metastasis. Mol Cancer Res (2013) 0.97
Lipid metabolism in prostate cancer. Am J Clin Exp Urol (2014) 0.96
Heterogeneous epigenetic regulation of TIMP3 in prostate cancer. Epigenetics (2012) 0.94
Identification of candidate methylation-responsive genes in ovarian cancer. Mol Cancer (2007) 0.94
The oncogene ERG: a key factor in prostate cancer. Oncogene (2015) 0.93
MSMB variation and prostate cancer risk: clues towards a possible fungal etiology. Prostate (2014) 0.93
Meta-analysis of multiple microarray datasets reveals a common gene signature of metastasis in solid tumors. BMC Med Genomics (2011) 0.92
Bioengineered implantable scaffolds as a tool to study stromal-derived factors in metastatic cancer models. Cancer Res (2014) 0.92
PDLIM4, an actin binding protein, suppresses prostate cancer cell growth. Cancer Invest (2009) 0.92
Metabolomic profiling identifies biochemical pathways associated with castration-resistant prostate cancer. J Proteome Res (2013) 0.92
High Expression of PTGR1 Promotes NSCLC Cell Growth via Positive Regulation of Cyclin-Dependent Protein Kinase Complex. Biomed Res Int (2016) 0.91
Role of p63 in Development, Tumorigenesis and Cancer Progression. Cancer Microenviron (2012) 0.91
EZH2-Mediated H3K27me3 Is Involved in Epigenetic Repression of Deleted in Liver Cancer 1 in Human Cancers. PLoS One (2013) 0.89
A novel approach to identify driver genes involved in androgen-independent prostate cancer. Mol Cancer (2014) 0.89
CCAR1 promotes chromatin loading of androgen receptor (AR) transcription complex by stabilizing the association between AR and GATA2. Nucleic Acids Res (2013) 0.89
Novel molecular targets of Azadirachta indica associated with inhibition of tumor growth in prostate cancer. AAPS J (2011) 0.89
Persistent inflammation leads to proliferative neoplasia and loss of smooth muscle cells in a prostate tumor model. Neoplasia (2011) 0.89
Analytical platform evaluation for quantification of ERG in prostate cancer using protein and mRNA detection methods. J Transl Med (2015) 0.89
Comprehensive resequence analysis of a 97 kb region of chromosome 10q11.2 containing the MSMB gene associated with prostate cancer. Hum Genet (2009) 0.88
Supporting a role for the GTPase Rab7 in prostate cancer progression. PLoS One (2014) 0.87
ACK1 tyrosine kinase: targeted inhibition to block cancer cell proliferation. Cancer Lett (2013) 0.87
Osteoprotegerin in bone metastases: mathematical solution to the puzzle. PLoS Comput Biol (2012) 0.86
Top associated SNPs in prostate cancer are significantly enriched in cis-expression quantitative trait loci and at transcription factor binding sites. Oncotarget (2014) 0.86
ΔNp63α regulates Erk signaling via MKP3 to inhibit cancer metastasis. Oncogene (2012) 0.86
The androgen receptor controls expression of the cancer-associated sTn antigen and cell adhesion through induction of ST6GalNAc1 in prostate cancer. Oncotarget (2015) 0.85
DNA repair: the culprit for tumor-initiating cell survival? Cancer Metastasis Rev (2011) 0.84
Possible role of death receptor-mediated apoptosis by the E3 ubiquitin ligases Siah2 and POSH. Mol Cancer (2011) 0.84
The miR-124-prolyl hydroxylase P4HA1-MMP1 axis plays a critical role in prostate cancer progression. Oncotarget (2014) 0.84
Recurrent patterns of DNA methylation in the ZNF154, CASP8, and VHL promoters across a wide spectrum of human solid epithelial tumors and cancer cell lines. Epigenetics (2013) 0.83
Gene expression profiling and real-time PCR analyses identify novel potential cancer-testis antigens in multiple myeloma. J Immunol (2009) 0.83
An oncogenic role for the multiple endocrine neoplasia type 1 gene in prostate cancer. Prostate Cancer Prostatic Dis (2008) 0.83
Meta-Analysis of Public Microarray Datasets Reveals Voltage-Gated Calcium Gene Signatures in Clinical Cancer Patients. PLoS One (2015) 0.82
Androgen-responsive serum response factor target genes regulate prostate cancer cell migration. Carcinogenesis (2013) 0.82
Deficiency of DNA repair nuclease ERCC1-XPF promotes prostate cancer progression in a tissue recombination model. Prostate (2011) 0.80
Androgen-regulation of the protein tyrosine phosphatase PTPRR activates ERK1/2 signalling in prostate cancer cells. BMC Cancer (2015) 0.80
Zinc finger protein 185 is a liver metastasis-associated factor in colon cancer patients. Mol Clin Oncol (2014) 0.79
Functional antagonism of TMPRSS2-ERG splice variants in prostate cancer. Genes Cancer (2014) 0.79
Lentiviral vector-mediated insertional mutagenesis screen identifies genes that influence androgen independent prostate cancer progression and predict clinical outcome. Mol Carcinog (2015) 0.78
Basic helix loop helix (bHLH) transcription factor 3 (TCF3, E2A) is regulated by androgens in prostate cancer cells. Am J Cancer Res (2015) 0.78
Identification and Validation of PCAT14 as Prognostic Biomarker in Prostate Cancer. Neoplasia (2016) 0.77
The PI3K regulatory subunit gene PIK3R1 is under direct control of androgens and repressed in prostate cancer cells. Oncoscience (2015) 0.77
Proteomic analysis of zoledronic-acid resistant prostate cancer cells unveils novel pathways characterizing an invasive phenotype. Oncotarget (2015) 0.77
RAMP1 is a direct NKX3.1 target gene up-regulated in prostate cancer that promotes tumorigenesis. Am J Pathol (2013) 0.77
The enzymatic activity of apoptosis-inducing factor supports energy metabolism benefiting the growth and invasiveness of advanced prostate cancer cells. J Biol Chem (2012) 0.77
GABARAPL1 suppresses metastasis by counteracting PI3K/Akt pathway in prostate cancer. Oncotarget (2016) 0.77
Expression of YY1 correlates with progression and metastasis in esophageal squamous cell carcinomas. Onco Targets Ther (2014) 0.77
Role of YY1 in the pathogenesis of prostate cancer and correlation with bioinformatic data sets of gene expression. Genes Cancer (2014) 0.76
Resistance to docetaxel in prostate cancer is associated with androgen receptor activation and loss of KDM5D expression. Proc Natl Acad Sci U S A (2016) 0.76
Dysregulated methylation at imprinted genes in prostate tumor tissue detected by methylation microarray. BMC Urol (2013) 0.76
Reconstitution of the ERG Gene Expression Network Reveals New Biomarkers and Therapeutic Targets in ERG Positive Prostate Tumors. J Cancer (2015) 0.76
Inhibitory effect of RNA-mediated knockdown of zinc finger protein 91 pseudogene on pancreatic cancer cell growth and invasion. Oncol Lett (2016) 0.76
Familial prostate cancer: the damage done and lessons learnt. Nat Rev Urol (2013) 0.76
Death receptor 5 expression is inversely correlated with prostate cancer progression. Mol Med Rep (2014) 0.76
Considering race and the potential for ERG expression as a biomarker for prostate cancer. Per Med (2014) 0.75
Cytoplasmic Clusterin expression correlates with pancreatic neuroendocrine tumor size and pathological stage. Pancreas (2013) 0.75
Poly (A) Binding Protein Cytoplasmic 1 Is a Novel Co-Regulator of the Androgen Receptor. PLoS One (2015) 0.75
Importance of Estrogenic Signaling and Its Mediated Receptors in Prostate Cancer. Int J Mol Sci (2016) 0.75
Discovery Proteomics Identifies a Molecular Link between the Coatomer Protein Complex I and Androgen Receptor-dependent Transcription. J Biol Chem (2016) 0.75
Dual tumor suppressing and promoting function of Notch1 signaling in human prostate cancer. Oncotarget (2016) 0.75
SPINT2 Deregulation in Prostate Carcinoma. J Histochem Cytochem (2015) 0.75
Tumor B7-H1 is associated with poor prognosis in renal cell carcinoma patients with long-term follow-up. Cancer Res (2006) 8.21
Radical nephrectomy for pT1a renal masses may be associated with decreased overall survival compared with partial nephrectomy. J Urol (2008) 5.30
Costimulatory B7-H1 in renal cell carcinoma patients: Indicator of tumor aggressiveness and potential therapeutic target. Proc Natl Acad Sci U S A (2004) 5.13
Nephron sparing surgery for appropriately selected renal cell carcinoma between 4 and 7 cm results in outcome similar to radical nephrectomy. J Urol (2004) 3.92
Carbonic anhydrase IX is not an independent predictor of outcome for patients with clear cell renal cell carcinoma. J Clin Oncol (2007) 3.50
Solid renal tumors: an analysis of pathological features related to tumor size. J Urol (2003) 3.48
Prediction of progression after radical nephrectomy for patients with clear cell renal cell carcinoma: a stratification tool for prospective clinical trials. Cancer (2003) 3.33
PD-1 is expressed by tumor-infiltrating immune cells and is associated with poor outcome for patients with renal cell carcinoma. Clin Cancer Res (2007) 3.23
USP10 regulates p53 localization and stability by deubiquitinating p53. Cell (2010) 3.17
The impact of perioperative blood transfusion on cancer recurrence and survival following radical cystectomy. Eur Urol (2013) 3.11
Histological subtype is an independent predictor of outcome for patients with renal cell carcinoma. J Urol (2010) 3.06
Comprehensive Molecular Characterization of Papillary Renal-Cell Carcinoma. N Engl J Med (2015) 3.00
Sarcopenia in patients with bladder cancer undergoing radical cystectomy: impact on cancer-specific and all-cause mortality. Cancer (2014) 2.77
Overall survival and development of stage IV chronic kidney disease in patients undergoing partial and radical nephrectomy for benign renal tumors. Eur Urol (2012) 2.52
B7-H4 expression in renal cell carcinoma and tumor vasculature: associations with cancer progression and survival. Proc Natl Acad Sci U S A (2006) 2.24
B7-H3 ligand expression by prostate cancer: a novel marker of prognosis and potential target for therapy. Cancer Res (2007) 2.19
The International Society of Urological Pathology (ISUP) grading system for renal cell carcinoma and other prognostic parameters. Am J Surg Pathol (2013) 2.05
The Mayo Clinic experience with surgical management, complications and outcome for patients with renal cell carcinoma and venous tumour thrombus. BJU Int (2004) 2.00
The impact of histological reclassification during pathology re-review--evidence of a Will Rogers effect in bladder cancer? J Urol (2013) 1.99
Mutations in CHEK2 associated with prostate cancer risk. Am J Hum Genet (2003) 1.96
A p120 catenin isoform switch affects Rho activity, induces tumor cell invasion, and predicts metastatic disease. J Biol Chem (2008) 1.87
Genomic organization and expression analysis of B7-H4, an immune inhibitory molecule of the B7 family. J Immunol (2003) 1.82
Comparison of standardized and nonstandardized nuclear grade of renal cell carcinoma to predict outcome among 2,042 patients. Am J Clin Pathol (2002) 1.82
Charlson co-morbidity index as a predictor of outcome after surgery for renal cell carcinoma with renal vein, vena cava or right atrium extension. J Urol (2003) 1.81
A scoring algorithm to predict survival for patients with metastatic clear cell renal cell carcinoma: a stratification tool for prospective clinical trials. J Urol (2005) 1.80
Lymph node dissection at the time of radical nephrectomy for high-risk clear cell renal cell carcinoma: indications and recommendations for surgical templates. Eur Urol (2010) 1.76
Does partial cystectomy compromise oncologic outcomes for patients with bladder cancer compared to radical cystectomy? A matched case-control analysis. J Urol (2012) 1.75
Outcomes following partial nephrectomy by tumor size. J Urol (2008) 1.72
Costimulatory molecule B7-H1 in primary and metastatic clear cell renal cell carcinoma. Cancer (2005) 1.71
MicroRNAs and prostate cancer. Acta Biochim Biophys Sin (Shanghai) (2010) 1.64
Hypermethylation of genes for diagnosis and risk stratification of prostate cancer. Cancer Invest (2009) 1.64
Tubulocystic carcinoma of the kidney: clinicopathologic analysis of 31 cases of a distinctive rare subtype of renal cell carcinoma. Am J Surg Pathol (2009) 1.63
Perivascular epithelioid cell tumor (PEComa) of the urinary bladder: report of 3 cases and review of the literature. Am J Surg Pathol (2009) 1.60
Tumor-infiltrating Foxp3-CD4+CD25+ T cells predict poor survival in renal cell carcinoma. Clin Cancer Res (2007) 1.59
Carbonic anhydrase IX (CAIX) is not an independent predictor of outcome in patients with clear cell renal cell carcinoma (ccRCC) after long-term follow-up. BJU Int (2013) 1.59
AGR2, an androgen-inducible secretory protein overexpressed in prostate cancer. Genes Chromosomes Cancer (2005) 1.58
Renal carcinoid tumor: a clinicopathologic study of 21 cases. Am J Surg Pathol (2007) 1.57
Independent validation of the 2002 American Joint Committee on cancer primary tumor classification for renal cell carcinoma using a large, single institution cohort. J Urol (2005) 1.55
Impact of tumor size on the predictive ability of the pT3a primary tumor classification for renal cell carcinoma. J Urol (2007) 1.53
Outside case review of surgical pathology for referred patients: the impact on patient care. Arch Pathol Lab Med (2012) 1.46
Optimization of laser capture microdissection and RNA amplification for gene expression profiling of prostate cancer. BMC Mol Biol (2007) 1.44
Autophagy inhibition promotes paclitaxel-induced apoptosis in cancer cells. Cancer Lett (2011) 1.43
Histologic coagulative tumor necrosis as a prognostic indicator of renal cell carcinoma aggressiveness. Cancer (2005) 1.43
Is renal sinus fat invasion the same as perinephric fat invasion for pT3a renal cell carcinoma? J Urol (2005) 1.42
Cancer specific survival for patients with pT3 renal cell carcinoma-can the 2002 primary tumor classification be improved? J Urol (2005) 1.42
Primary vascular tumors and tumor-like lesions of the kidney: a clinicopathologic analysis of 25 cases. Am J Surg Pathol (2010) 1.41
A phase II trial of green tea in the treatment of patients with androgen independent metastatic prostate carcinoma. Cancer (2003) 1.41
Mononuclear cell infiltration in clear-cell renal cell carcinoma independently predicts patient survival. Cancer (2006) 1.40
Precocious puberty in a 7-year-old boy: a novel case. J Pediatr Urol (2009) 1.39
Identification of a soluble form of B7-H1 that retains immunosuppressive activity and is associated with aggressive renal cell carcinoma. Clin Cancer Res (2011) 1.38
Comparison of presentation and outcome for patients 18 to 40 and 60 to 70 years old with solid renal masses. J Urol (2005) 1.38
Independent validation of the 2010 American Joint Committee on Cancer TNM classification for renal cell carcinoma: results from a large, single institution cohort. J Urol (2011) 1.36
Loss of BAP1 protein expression is an independent marker of poor prognosis in patients with low-risk clear cell renal cell carcinoma. Cancer (2013) 1.36
Smooth muscle neoplasms of the urinary bladder: a clinicopathologic comparison of leiomyoma and leiomyosarcoma. Am J Surg Pathol (2002) 1.32
A multifactorial postoperative surveillance model for patients with surgically treated clear cell renal cell carcinoma. J Urol (2003) 1.31
Global methylation profiling for risk prediction of prostate cancer. Clin Cancer Res (2012) 1.30
Survivin and b7-h1 are collaborative predictors of survival and represent potential therapeutic targets for patients with renal cell carcinoma. Clin Cancer Res (2007) 1.30
Utility of ALK-1 protein expression and ALK rearrangements in distinguishing inflammatory myofibroblastic tumor from malignant spindle cell lesions of the urinary bladder. Mod Pathol (2007) 1.27
Adenomatoid tumor of the adrenal gland: a clinicopathologic study of five cases and review of the literature. Am J Surg Pathol (2003) 1.26
Should direct ipsilateral adrenal invasion from renal cell carcinoma be classified as pT3a? J Urol (2005) 1.24
Effect of geldanamycin on androgen receptor function and stability. Cell Stress Chaperones (2002) 1.24
Comparative performance of comorbidity indices for estimating perioperative and 5-year all cause mortality following radical cystectomy for bladder cancer. J Urol (2013) 1.21
Serum-soluble B7x is elevated in renal cell carcinoma patients and is associated with advanced stage. Cancer Res (2008) 1.21
High expression levels of survivin protein independently predict a poor outcome for patients who undergo surgery for clear cell renal cell carcinoma. Cancer (2006) 1.20
Frequent microsatellite instability in sporadic tumors of the upper urinary tract. Cancer Res (2002) 1.20
Dynamic outcome prediction in patients with clear cell renal cell carcinoma treated with radical nephrectomy: the D-SSIGN score. J Urol (2007) 1.19
The impact of squamous and glandular differentiation on survival after radical cystectomy for urothelial carcinoma. J Urol (2012) 1.19
Clear cell renal cell carcinoma: gene expression analyses identify a potential signature for tumor aggressiveness. Clin Cancer Res (2005) 1.18
Analysis of repeat nephron sparing surgery as a treatment option in patients with a solid mass in a renal remnant. J Urol (2008) 1.17
Identification of prognostic biomarkers for prostate cancer. Clin Cancer Res (2008) 1.17
Lineage relationship of Gleason patterns in Gleason score 7 prostate cancer. Cancer Res (2013) 1.16
Mate pair sequencing of whole-genome-amplified DNA following laser capture microdissection of prostate cancer. DNA Res (2012) 1.15
Second primary malignancies associated with renal cell carcinoma histological subtypes. J Urol (2006) 1.15
Renal cell carcinoma in the solitary kidney: an analysis of complications and outcome after nephron sparing surgery. J Urol (2002) 1.13
PDLIM4 repression by hypermethylation as a potential biomarker for prostate cancer. Clin Cancer Res (2006) 1.13
Outcomes and clinicopathologic variables associated with late recurrence after nephrectomy for localized renal cell carcinoma. Urology (2011) 1.11
Prognostic features of pathologic stage T1 renal cell carcinoma after radical nephrectomy. Urology (2002) 1.09
The ability of biomarkers to predict systemic progression in men with high-risk prostate cancer treated surgically is dependent on ERG status. Cancer Res (2010) 1.09
Postoperative surveillance for renal cell carcinoma: a multifactorial histological subtype specific protocol. BJU Int (2009) 1.09
Identification of differentially expressed genes in normal and malignant prostate by electronic profiling of expressed sequence tags. Cancer Res (2002) 1.08
Ki-67 and coagulative tumor necrosis are independent predictors of poor outcome for patients with clear cell renal cell carcinoma and not surrogates for each other. Cancer (2007) 1.07
ALK alterations in adult renal cell carcinoma: frequency, clinicopathologic features and outcome in a large series of consecutively treated patients. Mod Pathol (2012) 1.07
A novel prognostic model for patients with sarcomatoid renal cell carcinoma. BJU Int (2014) 1.06
Cysteine-rich secretory protein-3: a potential biomarker for prostate cancer. Cancer Epidemiol Biomarkers Prev (2002) 1.06
TFE3 rearrangements in adult renal cell carcinoma: clinical and pathologic features with outcome in a large series of consecutively treated patients. Am J Surg Pathol (2012) 1.05
Probasin promoter (ARR(2)PB)-driven, prostate-specific expression of the human sodium iodide symporter (h-NIS) for targeted radioiodine therapy of prostate cancer. Cancer Res (2003) 1.04
Expression of insulin-like growth factor I receptor and survival in patients with clear cell renal cell carcinoma. J Urol (2003) 1.04
Eligibility for neoadjuvant/adjuvant cisplatin-based chemotherapy among radical cystectomy patients. BJU Int (2013) 1.03
B7-H1 glycoprotein blockade: a novel strategy to enhance immunotherapy in patients with renal cell carcinoma. Urology (2005) 1.03
Maintaining clinical tissue archives and supporting human research: challenges and solutions. Arch Pathol Lab Med (2011) 1.03
The effect of bilaterality, pathological features and surgical outcome in nonhereditary renal cell carcinoma. J Urol (2003) 1.03
Oxidative stress and DNA methylation in prostate cancer. Obstet Gynecol Int (2010) 1.03